The Ethics Blog

A research blog from the Centre for Resarch Ethics & Bioethics (CRB)

Page 45 of 50

Moral tipping points

Yesterday, I read a thought-provoking article about biosecurity. It suggested novel ways of thinking about infectious diseases. According to traditional thinking, infectious diseases strike us from outside. Therefore, we protect us from such external threats by building more effective borders. We secure pure healthy spaces and protect these spaces from impure, diseased ones. The alternative […]

Continue reading

Panbanisha, 1986-2012

It saddens me to have to report that Panbanisha, the bonobo who understood more about humans than any other nonhuman – and more than most humans – died November 6, 2012, from respiratory illness. Meeting her made it obvious to me that the world is more-than-human and that we have to rethink the inherited cosmology. Pär […]

Continue reading

Wanted: two researchers to join our team

The Centre for Research Ethics and Bioethics (CRB) is currently recruiting two researchers. We are looking for creative persons who like multi-disciplinary collaboration and are fluent in English. 1. Researcher in health economics (UFV-PA 2012/2684): We are looking for a person with a doctoral degree in health economics with documented skills in Discrete Choice Experiments. […]

Continue reading

Is there a need for a retractions database?

I wrote a while ago about drug companies as whistle blowers. Evidently, the pharmaceutical industry wastes more and more resources unsuccessfully trying to replicate published research studies. The amount of irreproducible published research surprised me. If there is such a trend, questions accumulate. Are researchers becoming increasingly careless, or even fraudulent? Are researchers acting under too […]

Continue reading

Drug companies as whistleblowers

Some years ago, John Ioannidis warned that most published research findings probably are false. More recently, the drug companies Bayer and Amgen reported that their attempts to replicate scientifically published studies that could be a basis for new drug development most often fail. Amgen, for example, failed to replicate 47 of 53 oncology and hematology […]

Continue reading

No consent for maintaining high-quality health care?

Collecting biological samples and health information from healthy donors in the construction of biobanks and research registers obviously requires the donors’ informed consent. But is a similar demand for consent reasonable when patients provide their doctor with samples for diagnosis, undergo medical examination and treatment, and answer the doctor’s questions? Or can patients be expected […]

Continue reading
« Older posts Newer posts »